Does the media refer more to NGNE or RXRX?

In the previous week, Recursion Pharmaceuticals had 10 more articles in the media than Neurogene. MarketBeat recorded 13 mentions for Recursion Pharmaceuticals and 3 mentions for Neurogene. Recursion Pharmaceuticals' average media sentiment score of 0.57 beat Neurogene's score of 0.39 indicating that Recursion Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurogene 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Recursion Pharmaceuticals 4 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is NUVB or NGNE more profitable?

Neurogene has a net margin of 0.00% compared to Nuvation Bio's net margin of -102.06%. Neurogene's return on equity of -37.88% beat Nuvation Bio's return on equity. Company Net Margins Return on Equity Return on Assets Nuvation Bio -102.06% -44.10% -23.80% Neurogene N/A -37.88% -34.70%

Does the media refer more to NUVB or NGNE?

In the previous week, Neurogene had 1 more articles in the media than Nuvation Bio. MarketBeat recorded 3 mentions for Neurogene and 2 mentions for Nuvation Bio. Nuvation Bio's average media sentiment score of 0.72 beat Neurogene's score of 0.39 indicating that Nuvation Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neurogene 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer NGNE or STOK?

In the previous week, Stoke Therapeutics had 4 more articles in the media than Neurogene. MarketBeat recorded 7 mentions for Stoke Therapeutics and 3 mentions for Neurogene. Stoke Therapeutics' average media sentiment score of 1.06 beat Neurogene's score of 0.39 indicating that Stoke Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurogene 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Stoke Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is LKFT or NGNE more profitable?

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Neurogene's return on equity. Company Net Margins Return on Equity Return on Assets Lakefront Biotherapeutics American Depositary Shares N/A N/A N/A Neurogene N/A -37.88% -34.70%

Which has higher earnings and valuation, PGEN or NGNE?

Neurogene has lower revenue, but higher earnings than Precigen. Neurogene is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Precigen $9.68M 188.57 -$250.64M -$1.18 N/A Neurogene $930K 663.94 -$90.35M -$4.55 N/A

Is PGEN or NGNE more profitable?

Neurogene has a net margin of 0.00% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Neurogene's return on equity. Company Net Margins Return on Equity Return on Assets Precigen -646.99% 717.50% 58.48% Neurogene N/A -37.88% -34.70%

Does the media favor PGEN or NGNE?

In the previous week, Precigen and Precigen both had 3 articles in the media. Precigen's average media sentiment score of 1.18 beat Neurogene's score of 0.39 indicating that Precigen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precigen 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neurogene 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Neurogene (NGNE) Competitors

$39.08 +0.76 (+1.98%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$39.66 +0.58 (+1.48%)

As of 07:23 AM Eastern

Compare

NGNE vs. RXRX, NUVB, STOK, LKFT, and PGEN

Should you buy Neurogene stock or one of its competitors? MarketBeat compares Neurogene with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Neurogene include Recursion Pharmaceuticals (RXRX), Nuvation Bio (NUVB), Stoke Therapeutics (STOK), Lakefront Biotherapeutics American Depositary Shares (LKFT), and Precigen (PGEN). These companies are all part of the "pharmaceutical products" industry.

How does Neurogene compare to Recursion Pharmaceuticals?

Neurogene (NASDAQ:NGNE) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

Neurogene has higher earnings, but lower revenue than Recursion Pharmaceuticals. Neurogene is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurogene	$930K	663.94	-$90.35M	-$4.55	N/A
Recursion Pharmaceuticals	$74.68M	23.70	-$644.76M	-$1.20	N/A

Neurogene presently has a consensus price target of $84.83, indicating a potential upside of 117.08%. Recursion Pharmaceuticals has a consensus price target of $8.10, indicating a potential upside of 142.51%. Given Recursion Pharmaceuticals' higher possible upside, analysts plainly believe Recursion Pharmaceuticals is more favorable than Neurogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurogene	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Neurogene has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -842.95%. Neurogene's return on equity of -37.88% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurogene	N/A	-37.88%	-34.70%
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%

In the previous week, Recursion Pharmaceuticals had 10 more articles in the media than Neurogene. MarketBeat recorded 13 mentions for Recursion Pharmaceuticals and 3 mentions for Neurogene. Recursion Pharmaceuticals' average media sentiment score of 0.57 beat Neurogene's score of 0.39 indicating that Recursion Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurogene	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Recursion Pharmaceuticals	4 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Neurogene has a beta of 1.68, suggesting that its share price is 68% more volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1, suggesting that its share price has a similar volatility profile to the broader market.

52.4% of Neurogene shares are owned by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 11.7% of Neurogene shares are owned by company insiders. Comparatively, 6.7% of Recursion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Neurogene beats Recursion Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Neurogene compare to Nuvation Bio?

Nuvation Bio (NYSE:NUVB) and Neurogene (NASDAQ:NGNE) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

61.7% of Nuvation Bio shares are owned by institutional investors. Comparatively, 52.4% of Neurogene shares are owned by institutional investors. 30.1% of Nuvation Bio shares are owned by insiders. Comparatively, 11.7% of Neurogene shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Neurogene has a net margin of 0.00% compared to Nuvation Bio's net margin of -102.06%. Neurogene's return on equity of -37.88% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	-102.06%	-44.10%	-23.80%
Neurogene	N/A	-37.88%	-34.70%

Nuvation Bio has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market. Comparatively, Neurogene has a beta of 1.68, meaning that its stock price is 68% more volatile than the broader market.

In the previous week, Neurogene had 1 more articles in the media than Nuvation Bio. MarketBeat recorded 3 mentions for Neurogene and 2 mentions for Nuvation Bio. Nuvation Bio's average media sentiment score of 0.72 beat Neurogene's score of 0.39 indicating that Nuvation Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvation Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neurogene	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Neurogene has lower revenue, but higher earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$62.90M	32.58	-$204.63M	-$0.43	N/A
Neurogene	$930K	663.94	-$90.35M	-$4.55	N/A

Nuvation Bio presently has a consensus target price of $12.38, indicating a potential upside of 110.28%. Neurogene has a consensus target price of $84.83, indicating a potential upside of 117.08%. Given Neurogene's stronger consensus rating and higher probable upside, analysts plainly believe Neurogene is more favorable than Nuvation Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Neurogene	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Neurogene beats Nuvation Bio on 10 of the 17 factors compared between the two stocks.

How does Neurogene compare to Stoke Therapeutics?

Neurogene (NASDAQ:NGNE) and Stoke Therapeutics (NASDAQ:STOK) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

Neurogene currently has a consensus target price of $84.83, indicating a potential upside of 117.08%. Stoke Therapeutics has a consensus target price of $42.00, indicating a potential upside of 44.18%. Given Neurogene's stronger consensus rating and higher possible upside, research analysts clearly believe Neurogene is more favorable than Stoke Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurogene	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00
Stoke Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Neurogene has a beta of 1.68, indicating that its share price is 68% more volatile than the broader market. Comparatively, Stoke Therapeutics has a beta of 1.17, indicating that its share price is 17% more volatile than the broader market.

In the previous week, Stoke Therapeutics had 4 more articles in the media than Neurogene. MarketBeat recorded 7 mentions for Stoke Therapeutics and 3 mentions for Neurogene. Stoke Therapeutics' average media sentiment score of 1.06 beat Neurogene's score of 0.39 indicating that Stoke Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurogene	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Stoke Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

52.4% of Neurogene shares are owned by institutional investors. 11.7% of Neurogene shares are owned by company insiders. Comparatively, 9.6% of Stoke Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Neurogene has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -529.20%. Neurogene's return on equity of -37.88% beat Stoke Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurogene	N/A	-37.88%	-34.70%
Stoke Therapeutics	-529.20%	-48.84%	-42.27%

Stoke Therapeutics has higher revenue and earnings than Neurogene. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurogene	$930K	663.94	-$90.35M	-$4.55	N/A
Stoke Therapeutics	$184.42M	9.84	-$6.89M	-$2.81	N/A

Summary

Neurogene beats Stoke Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Neurogene compare to Lakefront Biotherapeutics American Depositary Shares?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Neurogene (NASDAQ:NGNE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Lakefront Biotherapeutics American Depositary Shares presently has a consensus target price of $34.33, suggesting a potential upside of 16.50%. Neurogene has a consensus target price of $84.83, suggesting a potential upside of 117.08%. Given Neurogene's stronger consensus rating and higher possible upside, analysts clearly believe Neurogene is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.11
Neurogene	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market. Comparatively, Neurogene has a beta of 1.68, indicating that its stock price is 68% more volatile than the broader market.

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Neurogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
Neurogene	N/A	-37.88%	-34.70%

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. Comparatively, 52.4% of Neurogene shares are held by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by company insiders. Comparatively, 11.7% of Neurogene shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Lakefront Biotherapeutics American Depositary Shares had 1 more articles in the media than Neurogene. MarketBeat recorded 4 mentions for Lakefront Biotherapeutics American Depositary Shares and 3 mentions for Neurogene. Lakefront Biotherapeutics American Depositary Shares' average media sentiment score of 0.60 beat Neurogene's score of 0.39 indicating that Lakefront Biotherapeutics American Depositary Shares is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lakefront Biotherapeutics American Depositary Shares	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neurogene	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Neurogene. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.54	$363.05M	-$1.41	N/A
Neurogene	$930K	663.94	-$90.35M	-$4.55	N/A

Summary

Neurogene beats Lakefront Biotherapeutics American Depositary Shares on 9 of the 16 factors compared between the two stocks.

How does Neurogene compare to Precigen?

Precigen (NASDAQ:PGEN) and Neurogene (NASDAQ:NGNE) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings.

Neurogene has a net margin of 0.00% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Neurogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precigen	-646.99%	717.50%	58.48%
Neurogene	N/A	-37.88%	-34.70%

Precigen currently has a consensus target price of $12.50, indicating a potential upside of 144.14%. Neurogene has a consensus target price of $84.83, indicating a potential upside of 117.08%. Given Precigen's higher probable upside, equities research analysts plainly believe Precigen is more favorable than Neurogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precigen	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Neurogene	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Precigen and Precigen both had 3 articles in the media. Precigen's average media sentiment score of 1.18 beat Neurogene's score of 0.39 indicating that Precigen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precigen	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neurogene	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Precigen has a beta of 1, suggesting that its stock price has a similar volatility profile to the broader market.Comparatively, Neurogene has a beta of 1.68, suggesting that its stock price is 68% more volatile than the broader market.

33.5% of Precigen shares are owned by institutional investors. Comparatively, 52.4% of Neurogene shares are owned by institutional investors. 41.4% of Precigen shares are owned by insiders. Comparatively, 11.7% of Neurogene shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Neurogene has lower revenue, but higher earnings than Precigen. Neurogene is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precigen	$9.68M	188.57	-$250.64M	-$1.18	N/A
Neurogene	$930K	663.94	-$90.35M	-$4.55	N/A

Summary

Precigen beats Neurogene on 8 of the 15 factors compared between the two stocks.

Get Neurogene News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NGNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NGNE vs. The Competition

Export

Metric	Neurogene	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$605.53M	$3.68B	$6.86B	$12.44B
Dividend Yield	N/A	2.19%	2.68%	8.42%
P/E Ratio	-8.59	20.98	26.96	24.38
Price / Sales	663.94	311.10	518.38	91.92
Price / Cash	N/A	143.66	48.59	59.36
Price / Book	2.29	8.54	10.90	6.33
Net Income	-$90.35M	$23.83M	$3.59B	$331.02M
7 Day Performance	2.20%	-2.77%	-1.51%	-0.33%
1 Month Performance	30.88%	5.85%	2.76%	-1.29%
1 Year Performance	82.02%	52.15%	28.54%	21.30%

Neurogene Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NGNE Neurogene	3.1947 of 5 stars	$39.08 +2.0%	$84.83 +117.1%	+75.6%	$605.53M	$930K	N/A	90
RXRX Recursion Pharmaceuticals	3.3535 of 5 stars	$3.88 -2.1%	$8.10 +109.0%	-36.7%	$2.07B	$74.68M	N/A	400
NUVB Nuvation Bio	3.3268 of 5 stars	$5.85 +4.4%	$12.50 +113.9%	+173.2%	$2.03B	$62.90M	N/A	60
STOK Stoke Therapeutics	2.3849 of 5 stars	$32.50 +0.2%	$41.83 +28.7%	+141.5%	$2.02B	$184.42M	N/A	100	Positive News Analyst Forecast
LKFT Lakefront Biotherapeutics American Depositary Shares	1.7833 of 5 stars	$30.62 +0.9%	$36.50 +19.2%	-3.4%	$2.02B	$1.26B	N/A	1,310

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NGNE) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neurogene (NGNE) Competitors

NGNE vs. RXRX, NUVB, STOK, LKFT, and PGEN

How does Neurogene compare to Recursion Pharmaceuticals?

Summary

How does Neurogene compare to Nuvation Bio?

Summary

How does Neurogene compare to Stoke Therapeutics?

Summary

How does Neurogene compare to Lakefront Biotherapeutics American Depositary Shares?

Summary

How does Neurogene compare to Precigen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NGNE vs. The Competition

Neurogene Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neurogene (NGNE) Competitors

NGNE vs. RXRX, NUVB, STOK, LKFT, and PGEN

How does Neurogene compare to Recursion Pharmaceuticals?

Which has stronger earnings and valuation, NGNE or RXRX?

Do analysts recommend NGNE or RXRX?

Is NGNE or RXRX more profitable?

Does the media refer more to NGNE or RXRX?

Which has more risk & volatility, NGNE or RXRX?

Do institutionals & insiders have more ownership in NGNE or RXRX?

Summary

How does Neurogene compare to Nuvation Bio?

Do institutionals and insiders have more ownership in NUVB or NGNE?

Is NUVB or NGNE more profitable?

Which has more risk & volatility, NUVB or NGNE?

Does the media refer more to NUVB or NGNE?

Which has better valuation & earnings, NUVB or NGNE?

Do analysts rate NUVB or NGNE?

Summary

How does Neurogene compare to Stoke Therapeutics?

Do analysts rate NGNE or STOK?

Which has more risk & volatility, NGNE or STOK?

Does the media prefer NGNE or STOK?

Do insiders and institutionals believe in NGNE or STOK?

Is NGNE or STOK more profitable?

Which has preferable earnings & valuation, NGNE or STOK?

Summary

How does Neurogene compare to Lakefront Biotherapeutics American Depositary Shares?

Do analysts rate LKFT or NGNE?

Which has more risk and volatility, LKFT or NGNE?

Is LKFT or NGNE more profitable?

Do insiders & institutionals hold more shares of LKFT or NGNE?

Does the media favor LKFT or NGNE?

Which has stronger earnings & valuation, LKFT or NGNE?

Summary

How does Neurogene compare to Precigen?

Is PGEN or NGNE more profitable?

Do analysts prefer PGEN or NGNE?

Does the media favor PGEN or NGNE?

Which has more risk & volatility, PGEN or NGNE?

Do insiders & institutionals believe in PGEN or NGNE?

Which has higher earnings and valuation, PGEN or NGNE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NGNE vs. The Competition

Neurogene Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools